Induction by rapamycin and proliferation-promoting activity of Hspb1 in a *Tsc2*-deficient cell line

TAKAYUKI KITANO[1,2], KEIKO NISHIKAWA[1,2], TETSUYA TAKAGAKI[2],
YOSHINOBU SUGITANI[2], OKIO HINO[1,2] and TOSHIYUKI KOBAYASHI[1,2]

[1]Department of Molecular Pathogenesis, Juntendo University Graduate School of Medicine;
[2]Department of Pathology and Oncology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan

Abstract. Tuberous sclerosis complex (TSC) is an intractable inherited disease caused by a germline mutation in either the TSC complex subunit 1 (*TSC1*) or *TSC2* tumor suppressor genes. Recent progress in the treatment of TSC with rapamycin has provided benefits to patients with TSC. However, the complete elimination of tumors is difficult to achieve as regrowth often occurs after a drug is suspended; thus, more efficient medication and novel therapeutic targets are required. To overcome tumor remnants in the treatment of TSC, the present study investigated rapamycin-responsive signaling pathways in *Tsc2*-deficient tumor cells, focusing on heat shock protein-related pathways. The expression levels of heat shock protein family B (small) member 1 (Hspb1; also known as HSP25/27) were increased by rapamycin treatment. The phosphorylation of Hspb1 was also increased. The knockdown of *Hspb1* suppressed cell proliferation in the absence of rapamycin, and the overexpression of Hspb1 enhanced cell proliferation both in the presence and absence of rapamycin. Pathways associated with Hspb1 may present target candidates for treatment of TSC.

Introduction

Tuberous sclerosis complex (TSC) is a hereditary intractable disease characterized by various neoplastic lesions and psychoneurotic symptoms. Currently, mTOR inhibitors (rapamycin and its derivatives) are used to treat TSC due to the fact that loss of the causative gene (*TSC1* or *TSC2*) (1,2) results in the increased activity of mTOR kinase complex 1 (mTORC1) in the pathological process of TSC (3-8). While therapeutic benefits have been obtained to some extent in the

reduction of neoplastic lesions (9,10), the lack of complete tumor eradication (9), the side effects associated with long-term drug administration (such as interstitial pneumonia, severe stomatitis and immunosuppression) (11), and the sporadic occurrence of unresponsive cases has led to the urgent need to develop new therapeutic options.

Numerous studies have attempted to identify new drug targets for TSC in order to improve treatment. For example, rapamycin has been shown to induce feedback activation of pro-oncogenic kinases upstream of mTORC1, such as Akt and mitogen-activated protein kinase (MAPK), in TSC gene-deficient tumor cells (12-14). These kinases promote cell proliferation in rapamycin-treated TSC gene-deficient tumor cells (15). Studies have shown that endoplasmic (ER) stress is involved in the mechanism underlying negative feedback regulation by hyper-activated mTORC1 (16). Autophagy is activated by rapamycin independent of such feedback regulation and might support the proliferation of TSC gene-deficient tumor cells by providing free amino acids (17,18). These rapamycin-responsive pathways are thought to be candidate for drug targets. The single intervention of these pathways, along with certain rapamycin combination treatments for TSC gene-deficient tumors have been tested using cellular and animal models (15,18-20). While some of these interventions were effective, none have been applied in practical scenarios.

Many reports in the literature have addressed the dysregulation of mTORC1-independent signaling pathways in TSC gene deficiency. Because the protein complex of TSC1/TSC2 gene products (hamartin/tuberin) directly regulates the GTP-binding protein Rheb as a GTPase-activating protein (GAP), researchers have attempted to identify new pathways downstream of Rheb (21,22). For example, the contribution of PAK2 has already been demonstrated (23). In terms of neuropsychiatric disorders, previous research identified that the GDP-binding form of Rheb downregulates the expression levels of syntenin in an mTORC1-independent manner and helps to maintain the appropriate formation of the spine (24,25). The contribution of syntenin-related pathways in TSC-related tumorigenesis has yet to be reported. There are many other reports relating to mTORC1- and Rheb-independent pathways, although these findings have yet to be applied clinically.

Correspondence to: Dr Toshiyuki Kobayashi, Department of Molecular Pathogenesis, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
E-mail: koba396@juntendo.ac.jp

In addition, heat shock protein (HSP)-related pathways have been implicated in the development and progression of cancers (26). The expression levels of HSP, especially HSP70, HSP90, and Hspb1 (HSP25/27), have been identified as markers of the stage and prognosis of various cancers (26,27). These HSPs are thought to represent therapeutic targets for the treatment of cancer (26). Research has identified an interaction between hamartin and HSP70; this interaction was found to regulate apoptosis in TSC (28). Other research has shown that harmatin acts as a chaperone for HSP90 (29). However, the significance of these functions in the pathogenesis of TSC has yet to be fully elucidated. Furthermore, the relationship between Hspb1 and TSC-related tumorigenesis and therapy has yet to be defined.

In an attempt to identify key pathways for the development of new drugs, we analyzed rapamycin-induced changes in *Tsc2*-deficient tumor cells from an animal model of TSC (30-32). In this study, we focused on the pathways related to Hspb1 and found identified their role in the proliferation of *Tsc2*-deficient cells under rapamycin treatment.

Materials and methods

Cell culture. A *Tsc2*-deficient kidney tumor cell line, MKOC1-277 (MKOC) was established in our laboratory from the *Tsc2* knockout mouse and, together with its derivatives, had been used in various researches (30-35). MKOC cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml of penicillin and 100 μg/ml of streptomycin. Rapamycin (Sigma-Aldrich, Darmstadt, Germany) treatment was performed with dimethylsulfoxide (DMSO) as a vehicle. HeLa, COS7 and Plat-E cells (COSMO BIO, Tokyo, Japan) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS, 1 μg/ml of puromycin, 100 U/ml of penicillin and 100 μg/ml of streptomycin. In the case of Plat-E cells, 10 μg/ml of blasticidin was also added. All cell cultures were performed at 37°C with 5% CO_2. SB203580 was purchased from Sigma.

Cell proliferation assays. Cell proliferation was assessed with the 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay system (Roche, Basel, Switzerland) in accordance with the manufacturer's guidelines using 96-well plates. To 200 μl of culture medium, XTT reagent (50 μl) was added to each well and incubated for 4 h. Measurement of the absorbance at 450 nm (reference wavelength of 650 nm) was performed with a microplate reader (Benchmark Plus-microplate Spectrophotometer; Bio-Rad, Hercules, United States).

Western blot analysis. Cell lysates were prepared in Laemmli's sample buffer for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Protein concentration was determination by DC Protein Assays (Bio-Rad). Equal amounts of proteins were separated by SDS-PAGE using standard methodology and proteins were transferred to nylon membranes (Millipore, Burlington, United States). For blocking and antibody reactions, we used 1% skimmed milk/Tris buffered saline supplemented with 0.05% of Tween 20 (TBST). Anti-mouse or anti-rabbit Envision HRP-conjugate (DAKO, K4001 or K4003, respectively) was used as secondary antibodies. SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, Waltham, United States) or Immobilon Forte (Millipore) was used for the development of signals. A Bio-Rad ChemiDoc MP imaging system was used for the detection and analysis of signals. We used several different primary antibodies: anti-HSP27 (#sc13132), -pHSP27(S82) (#sc166693), -Hsp70 (#sc24, #sc59569), and Hsp90 (#sc13119); these antibodies were purchased from Santa Cruz Biotechnology (Dallas, United States). We also used anti-pS6(S235/S236) (#2211), -S6 (#2217), -tuberin (#3612), and -ß-actin (#4970) antibodies from Cell Signaling Technology (Danvers, United States) and anti-α-tubulin (B-5-1-2, #T5168) from Sigma.

RNA interference (RNAi). Transfection of siRNA was performed with Lipofectamine RNAi MAX (Thermo Fisher Scientific) according to the manufacturer's protocol. Cells were treated with 10 nM siRNA for the *Hspb1* gene (5'-CGGAGG AGCUCACAGUGAATT-3' and 5'-UUCACUGUGAGCUCC UCCGGA-3') (36) or control RNA (Thermo Fisher Scientific, #4390843) for 48-72 h. To analyze cell proliferation, rapamycin treatment was started one day after siRNA transfection to avoid severe toxicity.

Plasmid construction. The full-length cDNA of mouse *Hspb1* was amplified using primers mHsp27-F, 5'-AAG AATTCCCAGTGCTTCTAGATCCTCA-3' (forward), and mHsp27-R, 5'-AACTCGAGGCAATGGCTATGGGAG ATAG-3' (reverse). The amplified fragment was digested with *Eco*RI and *Xho*I and subcloned into the pBabe-puro vector (pBabe-puro was a gift from Hartmut Land & Jay Morgenstern & Bob Weinberg (Addgene plasmid #1764 ; http://n2t.net/addgene:1764 ; RRID:Addgene_1764)) (37). The vector had been modified to contain the *Xho*I recognition sequence by introducing synthetic oligonucleotides to the cloning site. The resulting Hspb1 expression vector was designated as pBabe-mHSP27. To generate cDNA for the Ser86-to-Asp86 (S86D) Hspb1 mutant, PCRs were carried out with specific primers: mHsp27-F and H27ASPR1, 5'-ACC CCGCT<u>GTC</u>GAGCTGT-3' (reverse), H27ASPF1, 5'-ACA GCTC<u>GAC</u>AGCGGGGT-3' (forward), and mHsp27-R, using pBabe-mHSP27 as a template. Then, the two amplified fragments were mixed and a second PCR was performed using mHsp27-F and mHsp27-R to amplify the full-length cDNA. Similarly, cDNA for the Ser86-to-Ala86 (S86A) Hspb1 mutant (pBabe-mHsp27-S86A) was amplified using the following primers: mHsp27F, H27ALAR1, 5'-ACCCCG CTT<u>GC</u>GAGCTGT-3' (reverse), H27ALAF1, 5'-ACAGCTC <u>GCA</u>AGCGGGGT-3' (forward), and mHsp27R. The resulting full length mutant cDNA fragments were cloned into the pBabe-puro vector to generate pBabe-mHSP27-S86D and -S86A. The accuracy of the cDNA sequence was checked by the dideoxy-sequencing method using an ABI 310 sequencer (Thermo Fisher Scientific).

Establishment of stable cell lines. Plat-E cells (pre-cultured without puromycin or blasticidin) were transfected with the vector for wild-type, S86A and S86D Hspb1, or empty vector using FuGENE6 transfection reagent (Promega, Wisconsin,

Figure 1. Analysis of Hspb1 expression in TSC complex subunit 2-deficient kidney tumor cells (MKOC). (A) MKOC cells were treated with 20 nM Rapa or vehicle only (DMSO) for 48 h. Cell proliferation was then analyzed by XTT assays. Data are representative of three independent experiments. Each experiment was performed with three independent culture wells. The data are presented as the mean + SD. ***P<0.001 compared with Rapa. (B) MKOC cells were treated with 20 nM Rapa or vehicle only (DMSO) for 24 h. Total cell lysates were analyzed by western blotting with the indicated antibodies (Hspb1, pHspb1, pS6, S6 and βactin). (C) MKOC cells were treated with 20 nM Rapa or vehicle only (DMSO) for 24 h. Total cell lysates were analyzed by western blotting with the indicated antibodies (Hspb1, Hsp90, Hsp70 and α-tubulin). Hsp90, heat shock protein 90; Hsp70, heat shock protein 70; Hspb1, heat shock protein family B (small) member 1; MKOC, MKOC1-277; p, phosphorylated; Rapa, rapamycin.

United States) according to the manufacturer's protocol. Next, 48 h after transfection, we collected the culture media which was filtered through a 0.45-μm filter. Then, we added polybrene to a final concentration of 8 μg/ml. MKOC cells were infected with supernatant and the selection of stably transduced cells with 0.6 μg/ml of puromycin was started 48 h after infection. Established cell lines were maintained in the presence of puromycin in the medium.

Statistical analysis. Statistical analyses were performed with Microsoft Excel software (Microsoft, Redmond, United States), and Statistical analysis program for pharmaceutical data (Osaka university, Osaka, Japan; http://www.gen-info. osaka-u.ac.jp/MEPHAS/tukey-e.html). The significance of difference was examined by unpaired Student's t-test for two groups comparison, and one-way ANOVA followed by Tukey's post hoc test for multiple groups comparison. A p value less than 0.05 was considered statistically significant.

Results

Hspb1 expression was upregulated by rapamycin treatment in Tsc2-deficient tumor cells. To analyze the levels of Hspb1 protein, we treated MKOC cells with rapamycin (20 nM) for 24 and 48 h and then performed western blotting. Rapamycin suppressed the proliferation of *Tsc2*-deficient cells by approximately 35% (P<0.001) (Fig. 1A). In this condition, we found that the amount of Hspb1 protein was increased by 24 h rapamycin treatment (Fig. 1B). The phosphorylation of Hspb1 on Ser86 (corresponding to Ser82 in human HSPB1), the main phosphorylation site that regulates oligomerization, was also upregulated, concomitant with an increase in the total amount of protein (Fig. 1B). Furthermore, rapamycin treatment did


Figure 2. Confirmation of Hspb1 expression in HeLa and COS7 cells. Cells were treated with 20 nM Rapa (+) or vehicle only (-) for 24 h. Total cell lysates were analyzed by western blotting with the indicated antibodies. Hspb1, heat shock protein family B (small) member 1; p, phosphorylated; Rapa, rapamycin.

not result in the increased expression of HSP70 and Hsp90 (Fig. 1C), thus revealing that each HSP responded differently to rapamycin. To ascertain whether these phenomena occurred generally in cultured cells, we investigated the effects of rapamycin on HSP expression in routine HeLa and COS7 cells. No induction of Hspb1 expression was observed in either HeLa or COS7 cells (Fig. 2). These results indicated that the

Figure 3. Analysis of MKOC cells transfected with *Hspb1* siRNA. (A) MKOC cells were treated with *Hspb1* siRNA for 48 h. Total cell lysates were analyzed by western blotting with the indicated antibodies. (B) MKOC cells were treated with siRNA (+) or siRNA (-) for 24 h. Subsequently, each group of cells was treated with 20 nM Rapa or vehicle only for 48 h. The start point of the drug treatment was defined as Day 0. Cell proliferation was analyzed by XTT assays. Data are representative of three independent experiments. Each experiment was performed with three independent culture wells. The data are presented as the mean + SD. *P<0.05 compared with siRNA (-) and Rapa (-); #P<0.05 compared with siRNA (+) and Rapa (-). Cont, control; Hspb1, heat shock protein family B (small) member 1; MKOC, MKOC1-277; siRNA, small interfering RNA; siRNA (+), *Hspb1* siRNA; siRNA (-), control RNA; Rapa, rapamycin; Rapa (-), vehicle only.

suppression of mTORC1 by rapamycin causes the upregulation of Hspb1 expression in *Tsc2*-deficient cells.

SiRNA for Hspb1 suppressed cell proliferation. To investigate whether Hspb1 exerted a positive or negative role in cell proliferation under rapamycin treatment, we used RNAi to suppress the expression of Hspb1. The efficacy of siRNA for the *Hspb1* gene was confirmed by western blotting analysis (Fig. 3A). *Hspb1* siRNA treatment significantly inhibited the proliferation of MKOC cells under normal culture condition (P<0.05) (Fig. 3B). Under the rapamycin treatment, however, the extent of inhibition was similar when compared between control RNA and *Hspb1* siRNA conditions (P<0.05 between DMSO and rapamycin without siRNAs; no significance between control and *Hspb1* siRNA under the rapamycin-treated condition) (Fig. 3B), thus suggesting that rapamycin-induced growth regulation may involve the suppression of Hspb1-related pathways.

The forced expression of Hspb1 enhanced proliferation under rapamycin treatment. Next, we analyzed the effects of the forced expression of Hspb1 on cell proliferation. We established MKOC cells stably expressing Hspb1 and control cells (Fig. 4A). When cultured without rapamycin for 48 h, the proliferation of HSP27-expressing cells was promoted when compared with control cells (P<0.05) (Fig. 4B). Under the action of rapamycin, there was also proliferation promoting activity in the wild-type Hspb1 (P<0.05) (Fig. 4B). These results suggested that the function of Hspb1 promoted proliferation in *Tsc2*-deficient cells even in the presence of rapamycin.

We also assayed the effect of Ser86 phosphorylation in Hspb1 upon cell proliferation by the forced expression of a phosphorylation-mimetic S86D mutant (D-mutant) and resistant S86A mutant (A-mutant) Hspb1 in MKOC cells (Fig. 4A). Western blotting revealed a reduction in pHspb1 antibody binding in D-mutant and A-mutant cases, thus suggesting that site-directed mutagenesis had been successfully accomplished. In the proliferation assays, both with and without rapamycin treatment, there was a reduction of proliferation-promoting activity in the A-mutant case (P<0.05 vs. wild-type case both with and without rapamycin) when compared with the wild-type case, thus suggesting that phosphorylation on S86 might be a positive regulator of proliferation-promoting activity in Hspb1 (Fig. 4A and B). However, there was no obvious difference in cell proliferation when compared between the A- and D-mutant (Fig. 4A and B). From these observations, it was difficult to conclude that Ser86 phosphorylation on Hspb1 affects cell proliferation.

Discussion

In this study, we focused on the stress-response pathways involving Hspb1 that have not been explored in the pathogenesis and treatment of TSC. We confirmed that Hsp27 was not increased by rapamycin treatment in other cells, a phenomenon that may be related to *Tsc2* mutation, thus, we decided to further analyze Hsp27. We found that the Hspb1 induced by rapamycin promoted cell proliferation in *Tsc2*-deficient tumor cells in culture.

There was no significant difference in proliferation inhibition at 24 h, but there was a difference in Hspb1 expression.

Figure 4. Analysis of MKOC1-277 cells stably expressing Hspb1 and its mutants. (A) Total cell lysates were analyzed by western blotting with the indicated antibodies. Cells were treated with (B) vehicle only or (C) 20 nM rapamycin for 48 h. Cell proliferation was analyzed by XTT assays. Data are representative of three independent experiments. Each experiment was performed with three independent culture wells. The data are presented as the mean + SD. $^{*}P<0.05$ compared with empty vector; $^{#}P<0.05$ compared with wild-type Hspb1. Empty, control empty vector; A-mutant, phosphorylation-resistant S86A-mutant; D-mutant, phosphorylation-mimetic S86D-mutant; Hspb1, heat shock protein family B (small) member 1; p, phosphorylated; W-Hspb1, wild-type Hspb1 overexpression.

Although the mechanism is unknown at present, we hypothesize that Hspb1 expression fluctuations occur quickly in response to rapamycin the network of proliferation inhibitory mechanisms (Fig. S1), and then actual cell proliferation suppression appears as a phenotype.

Previous studies have shown that the resistance to anti-cancer drugs in many cancers is associated with higher expression levels of Hspb1 (26). The findings of the present study suggest that Hspb1 might be responsible, at least in part, for tumor remnants then TSC is treated with rapamycin (9). In siRNA experiments, no effect of suppression of *Hspb1* was observed in addition to the action of rapamycin, but in forced expression experiments, a proliferation-promoting effect of increased Hspb1 expression appeared under the rapamycin treatment condition. In such a condition, it is presumed that the proliferation-promoting pathway that can be supported by Hspb1 expression was sufficiently suppressed, and that

further suppression of *Hspb1* by siRNA did not show any effect. In the case of forced expression experiments, it is presumed that the suppression of proliferation by rapamycin could be partly recovered by increased amount of Hspb1. The regulatory mechanisms of proliferation exerted by Hspb1 under rapamycin treatment remain unclear. Nonetheless, the combined treatment of TSC gene-deficient tumors with a drug targeting Hspb1-related pathway might be more effective when compared with the single use of rapamycin. It might be possible that the effect of Hspb1 suppression will appear at the concentration of rapamycin-related drugs acting during treatment.

In this study, we revealed the functional importance of Hspb1 in the proliferation of *Tsc2*-deficient cells. The mechanistic effect of Hspb1 has been implicated in the regulation of ferroptosis, a mechanism of cell death that is associated with iron metabolism (38,39). In *Hspb1*-suppressed cells, it is

possible that a proliferation suppressive mechanism related to ferroptosis might be induced.

In the present study, we also observed elevated levels of phosphorylation. However, the forced expression of phosphorylation-mimicking and non-phosphorylated mutants both showed slight attenuation of the proliferation-promoting effect. At present, the significance of phosphorylation remains unclear but should be investigated in the future.

A recent study found a possibility that Hspb1-related pathway might be a chemotherapeutic target of TSC-related neuropsychiatric disorders (40). To the best of our knowledge, the present study is the first to report the function of Hspb1 in the proliferation of TSC-related tumors. Further experiments are needed to determine whether other types of TSC gene-deficient cells, especially human-origin cells, show identical phenotypes.

In conclusion, we identified Hspb1 as a key molecule in the proliferation-supporting mechanism that occurs under rapamycin treatment. Intervention of the Hspb1-related pathway may increase the efficacy of rapamycin in the treatment of TSC. It is now necessary to perform *in vitro* as well as *in vivo* studies with animal models to clarify the importance of Hspb1 in the pathogenesis and treatment of TSC.

Availability of data and materials

The datasets used and/analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

TKi, OH and TKo designed the study. TKi, KN, TT, YS and TKo performed the experiments. TKi and TKo prepared the figures. TKi and TKo prepared the manuscript. TKi and TKo confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Henske EP, Jóźwiak S, Kingswood JC, Sampson JR and Thiele EA: Thiele: Tuberous sclerosis complex. Nat Rev Dis Primers 2: 16035, 2016.
2. Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, Frost MD, Fuchs Z, Gosnell ES, Gupta N, *et al*: Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 123: 50-66, 2021.
3. Inoki K, Li Y, Zhu T, Wu J and Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657, 2002.
4. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, Ru B and Pan D: Tsc tumor suppressor proteins antagonize amino-acid-TOR signaling. Nat Cell Biol 4: 699-704, 2002.
5. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N and Onda H: A mouse model ot TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in *Tsc1* null cells. Hum Mol Genet 11: 525-534, 2002.
6. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC and Blenis J: Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downatream signaling. Proc Natl Acad Sci USA 99: 13751-13756, 2002.
7. Kenerson HL, Aicher LD, True LD and Yeung RS: Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62: 5645-5650, 2002.
8. El-Hashemite N, Zhang H, Henske EP and Kwiatkowski DJ: Mutation in *TSC2* and activation of mammalian target of rapamycin signaling pathway in renal angiomyolipoma. Lancet 361: 1348-1349, 2003.
9. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, *et al*: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358: 140-151, 2008.
10. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T and Franz DN: Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363: 1801-1811, 2010.
11. Davies M, Saxena A and Kingswood JC: Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: A practical guide. Orphanet J Rare Dis 12: 35, 2017.
12. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ and Cantley LC: Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19: 1773-1778, 2005.
13. Wan X, Harkavy B, Shen N, Grohar P and Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940, 2007.
14. Carracedo A, Baselga J and Pandolfi PP: Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 7: 3805-3809, 2008.
15. Mi R, Ma J, Zhang D, Li L and Zhang H: Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. J Genet Genomics 36: 355-361, 2009.
16. Ozcan U, Ozcan L, Yilmaz E, Düvel K, Sahin M, Manning BD and Hotamisligil GS: Loss of the tuberous sclerosis complex tumor suppressors truggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 29: 541-551, 2008.
17. Yu J, Parkhitko AA and Henske EP: Mammalian target of rapamycin signaling and autophagy: Roles in lymphangioleiomyomatosis therapy. Proc Am Thorac Soc 7: 48-53, 2010.
18. Parkhitko A, Myachina F, Morrison TA, Hindi KM, Auricchio N, Karbowniczek M, Wu JJ, Finkel T, Kwiatkowski DJ, Yu JJ and Henske EP: Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci USA 108: 12455-12460, 2011.
19. Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H and Kwiatkowski D: Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer 8: 38, 2009.

20. Siroky BJ, Yin H, Babcock JT, Lu L, Hellmann AR, Dixon BP, Quilliam LA and Bissler JJ: Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress. Am J Physiol Renal Physiol 303: F831-F844, 2012.

21. Armijo ME, Campos T, Fuentes-Villalobos F, Palma ME, Pincheira R and Castro AF: Rheb signaling and tumorigenesis: mTORC1 and new horizons. Int J Cancer 138: 1815-1823, 2016.

22. Gau CL, Kato-Stankiewicz J, Jiang C, Miyamoto S, Guo L and Tamanoi F: Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Mol Cancer Ther 4: 918-926, 2005.

23. Alves MM, Fuhler GM, Queiroz KC, Scholma J, Goorden S, Anink J, Spek CA, Hoogeveen-Westerveld M, Bruno MJ, Nellist M, et al: PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for tuberous sclerosis complex. Sci Rep 5: 14534, 2015.

24. Sugiura H, Yasuda S, Katsurabayashi S, Kawano H, Endo K, Takasaki K, Iwasaki K, Ichikawa M, Kobayashi T, Hino O and Yamagata K: Rheb activation disrupts spine synapse formation through accumulation of syntenin in tuberous sclerosis complex. Nat Commun 6: 6842, 2015.

25. Sugiura H, Shimada T, Moriya-Ito K, Goto JI, Fujiwara H, Ishii R, Shitara H, Taya C, Fujii S, Kobayashi T, et al: A farnesyltransferase inhibitor restores cognitive deficits in Tsc2$^{+/-}$ mice through inhibition of Rheb1. J Neurosci 23: 2598-2612, 2022.

26. Wu J, Liu T, Rios Z, Mei Q, Lin X and Cao S: Heat shock proteins and cancer. Trends Pharmacol Sci 38: 226-256, 2017.

27. Dimas DT, Perlepe CD, Sergentanis TN, Misitzis I, Kontzoglou K, Patsouris E, Kouraklis G, Psaltopoulou T and Nonni A: The prognostic significance of Hsp70/Hsp90 expression in breast cancer: A systematic review. Anticancer Res 38: 1551-1562, 2018.

28. Inoue H, Uyama H, Suzuki T, Kazami M, Hino O, Kobayashi T, Kobayashi K, Tadokoro T and Yamamoto Y: Phosphorylated hamartin-Hsp70 complex regulates apoptosis via mitochondrial localization. Biochem Biophys Res Commun 391: 1148-1153, 2010.

29. Woodford MR, Sager RA, Marris E, Dunn DM, Blanden AR, Murphy RL, Rensing N, Shapiro O, Panaretou B, Prodromou C, et al: Tumor suppressor Tsc1 is a new HSP90 co-chaperone that facilitates folding of kinase and non-kinase clients. EMBO J 36: 3650-3665, 2017.

30. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O and Noda T: Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 59: 1206-1211, 1999.

31. Piao X, Kobayashi T, Wang L, Shiono M, Takagi Y, Sun G, Abe M, Hagiwara Y, Zhang D, Okimoto K, et al: Regulation of folliculin (the BHD gene product) phosphorylation by Tsc2-mTOR pathway. Biochem Biophys Res Commun 389: 16-21, 2009.

32. Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM and Krymskaya VP: Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med 4: 154ra134, 2012.

33. Okura H, Kobayashi T, Koike M, Ohsawa M, Zhang D, Arai H, Uchiyama Y and Hino O: Tuberin activates and controls the distribution of Rac1 via association with p62 and ubiquitin through the mTORC1 signaling pathway. Int J Oncol 43: 447-456, 2013.

34. Sato T, Akasu H, Shimono W, Matsu C, Fujiwara Y, Shibagaki Y, Heard JJ, Tamanoi F and Hattori S: Rheb protein binds CAD (Carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and Carbamoyl-phosphate synthetase (CPSase) activity. J Biol Chem 290: 1096-1105, 2015.

35. Liu HJ, Lizotte PH, Du H, Speranza MC, Lam HC, Vaughan S, Alesi N, Wong KK, Freeman GJ, Sharpe AH and Henske EP: TSC2-deficient tumors have evidence of T cell exhaustion and respond anti-PD-1/anti-CTLA-4 immunotherapy. JCI Insight 3: e98674, 2018.

36. Wang HX, Yang Y, Guo H, Hou DD, Zheng S, Hong YX, Cai YF, Huo W, Qi RQ, Zhang L, et al: HSPB1 deficiency sensitizes melanoma cells to hyperthermia induced cell death. Oncotarget 7: 67449-67462, 2016.

37. Morgenstern JP and Land H: Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18: 3587-3596, 1990.

38. Sun X, Ou Z, Xie M, Kang R, Fan Y, Niu X, Wang H, Cao L and Tang D: HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene 34: 5617-5625, 2015.

39. Liu CC, Li HH, Lin JH, Chiang MC, Hsu TW, Li AF, Yen DH, Hsu HS and Hung SC: Esophageal cancer stem-like cells resist ferroptosis-induced cell death by active Hsp27-GPX4 pathway. Biomolecules 12: 48, 2021.

40. Di Nardo A, Lenoël I, Winden KD, Rühmkorf A, Modi ME, Barrett L, Ercan-Herbst E, Venugopal P, Behne R, Lopes CAM, et al: Phenotypic screen with TSC-deficient neurons reveals heat-shock machinery as a druggable pathway for mTORC1 and reduced cilia. Cell Rep 31: 107780, 2020.